JP5373553B2 - コラーゲンを基にした止血スポンジ - Google Patents
コラーゲンを基にした止血スポンジ Download PDFInfo
- Publication number
- JP5373553B2 JP5373553B2 JP2009248693A JP2009248693A JP5373553B2 JP 5373553 B2 JP5373553 B2 JP 5373553B2 JP 2009248693 A JP2009248693 A JP 2009248693A JP 2009248693 A JP2009248693 A JP 2009248693A JP 5373553 B2 JP5373553 B2 JP 5373553B2
- Authority
- JP
- Japan
- Prior art keywords
- sponge
- collagen
- thrombin
- mixture
- fibrinogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000008186 Collagen Human genes 0.000 title claims description 53
- 108010035532 Collagen Proteins 0.000 title claims description 53
- 229920001436 collagen Polymers 0.000 title claims description 53
- 230000002439 hemostatic effect Effects 0.000 title claims description 14
- 229960004072 thrombin Drugs 0.000 claims description 47
- 108090000190 Thrombin Proteins 0.000 claims description 46
- 229940012952 fibrinogen Drugs 0.000 claims description 31
- 108010049003 Fibrinogen Proteins 0.000 claims description 30
- 102000008946 Fibrinogen Human genes 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 238000004108 freeze drying Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000000512 collagen gel Substances 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 239000008240 homogeneous mixture Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 238000007605 air drying Methods 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000004026 adhesive bonding Methods 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000023555 blood coagulation Effects 0.000 description 7
- 230000023597 hemostasis Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003106 tissue adhesive Substances 0.000 description 6
- 108010071289 Factor XIII Proteins 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229940012444 factor xiii Drugs 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002760 pro-activator Effects 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 108010034963 tachocomb Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010000196 Factor XIIIa Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- 239000008380 degradant Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000000937 inactivator Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-UHFFFAOYSA-N 3-(1-phenylethyl)-4-imidazolecarboxylic acid ethyl ester Chemical compound CCOC(=O)C1=CN=CN1C(C)C1=CC=CC=C1 NPUKDXXFDDZOKR-UHFFFAOYSA-N 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108010033702 ethnor Proteins 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003869 thrombin derivative Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/102—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/08—Collagen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/22—Blood coagulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Surgery (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
乾燥コラーゲン1g等量(液状、ペースト状、繊維状または粉状のコラーゲン物質から)を0.01Mのクエン酸100mlに溶解した。均一の液状ゲルができるまで混合物を振った。4℃で攪拌を続けながら、NaOH溶液を加えてpHを7.2に調節した。このゲルは1%コラーゲンを含んでいた。同様に0.25%コラーゲンゲルを製造した。
実施例1で得た1%コラーゲンゲル60ml を1000 IU/ml トロンビン溶液 ( HUMAN THROMBIN IMMUNO AG ) 5ml と4℃で混合した。均質の混合物を4℃に予め冷やした10X10cmのトレイ上に注いだ。トレイを4℃に予め冷やした凍結乾燥機の凍結室に移した。次いで凍結機を動かして-20℃まで下げ、15%の水分含量になるまで産物を凍結乾燥した。
実施例1で得た1%コラーゲンゲル60ml を4℃に予め冷やした10X10cmのトレイ上に注いだ。トレイを4℃に予め冷やした凍結乾燥機の凍結室に移した。次いで凍結機を動かして-5℃まで下げ、産物を-5℃で凍結した。
ヘパリン処理ブタにおける肝切除モデルを用いて、実施例2で得た産物I、トロンビンを含有しないコラーゲン製品およびTachoComb(商標名、Nycomed)を比較した。
Claims (23)
- コラーゲンおよびその中に均質に分散したトロンビンを基とした止血スポンジであり、該スポンジは、乾燥され、2%から25%の水分を含む止血スポンジ。
- 10から20%の水分を含む請求項1のスポンジ。
- スポンジが凍結乾燥または空気乾燥されている、請求項1または2のスポンジ。
- pHが6から8の範囲にあることを特徴とする、請求項1−3のいずれかのスポンジ。
- 厚さが3mmから10mmまでであることを特徴とする、請求項1−4のいずれかのスポンジ。
- トロンビンの含量がg当たり1,000 - 10,000 Uであることを特徴とする、請求項1−5のいずれかのスポンジ。
- 薬理的活性物質、保存剤、抗フィブリノーゲン分解物質、抗生物質、抗菌剤、抗真菌剤、成長因子、酵素または酵素阻害剤をさらに含有する、請求項1−6のいずれかのスポンジ。
- 請求項1−7のいずれかのスポンジ、および止血性であり、該スポンジに対して粘着性の追加層を含む創傷被覆剤。
- 追加層がコラーゲンからなる、請求項8の創傷被覆剤。
- 追加層がフィブリノーゲンを含有する、請求項8の創傷被覆剤。
- 追加層がフィブリノーゲンをコラーゲンとの混合物として含有する、請求項10の創傷被覆剤。
- 創傷被覆剤をつくるためのキットであって、
a)請求項1−7のいずれかのスポンジ、および
b)フィブリノーゲンを含み、さらに、
c)薬理的活性物質を含んでいてもよい、キット。 - フィブリノーゲンが貯蔵安定形態で存在する請求項12のキット。
- コラーゲン性原料物質を酸性化してコラーゲンゲルを得、ゲルをトロンビンと混合して、均質の混合物を得、該混合物を2から25%の水分含量まで乾燥することによる請求項1−7のいずれかのスポンジを製造する方法。
- 該混合物を10から20%の水分含量まで乾燥する請求項14の方法。
- 乾燥を凍結乾燥または空気乾燥により行う請求項14または15の方法。
- NaOHまたはCa(OH)2から選択されるアルカリ溶液を加えることによりゲルまたは混合物を中性にする、請求項14−16のいずれかの方法。
- 混合物を凍結乾燥して、乾燥スポンジを得、該乾燥スポンジを2から25%の水分含量を有するスポンジを得るために十分な量の水と接触させる、請求項14−17のいずれかの方法。
- 混合物を一定の形状で凍結乾燥する、請求項14−18のいずれかの方法。
- 追加物質として生理的活性物質を混合物に加える、請求項14−19のいずれかの方法。
- コラーゲン性原料物質、固形のゲルおよび/またはスポンジを照射により滅菌する、請求項14−20のいずれかの方法。
- コラーゲン性原料物質がコラーゲン末である、請求項21の方法。
- 追加層が連続的または同時の乾燥、凍結乾燥、架橋または膠付けによりスポンジに結合される、請求項14−22のいずれかの方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA611/96 | 1996-04-04 | ||
AT61196 | 1996-04-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09535819A Division JP2000510357A (ja) | 1996-04-04 | 1997-04-02 | コラーゲンを基にした止血スポンジ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010046516A JP2010046516A (ja) | 2010-03-04 |
JP2010046516A5 JP2010046516A5 (ja) | 2011-01-27 |
JP5373553B2 true JP5373553B2 (ja) | 2013-12-18 |
Family
ID=3495187
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09535819A Withdrawn JP2000510357A (ja) | 1996-04-04 | 1997-04-02 | コラーゲンを基にした止血スポンジ |
JP2009248693A Expired - Lifetime JP5373553B2 (ja) | 1996-04-04 | 2009-10-29 | コラーゲンを基にした止血スポンジ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09535819A Withdrawn JP2000510357A (ja) | 1996-04-04 | 1997-04-02 | コラーゲンを基にした止血スポンジ |
Country Status (13)
Country | Link |
---|---|
US (1) | US6649162B1 (ja) |
EP (1) | EP0891193B1 (ja) |
JP (2) | JP2000510357A (ja) |
AT (1) | ATE247494T1 (ja) |
AU (1) | AU726163B2 (ja) |
CA (1) | CA2251475C (ja) |
CZ (1) | CZ318998A3 (ja) |
DE (1) | DE69724243T2 (ja) |
HU (1) | HUP9903586A3 (ja) |
NO (1) | NO314070B1 (ja) |
RU (1) | RU2193897C2 (ja) |
SK (1) | SK284693B6 (ja) |
WO (1) | WO1997037694A1 (ja) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
DE10025001A1 (de) * | 2000-05-22 | 2001-11-29 | Aventis Behring Gmbh | Gewebekleber mit verbesserten anti-adhäsiven Eigenschaften |
JP4399615B2 (ja) * | 1999-09-27 | 2010-01-20 | シスメックス株式会社 | トロンビンの安定化手段および組成物 |
CA2400398C (en) * | 2000-03-09 | 2010-05-04 | Syntacoll Ag | Multilayer collagen matrix for tissue reconstruction |
AT411326B (de) * | 2000-06-20 | 2003-12-29 | Biering Wolfgang | Hämostatische collagen-pellets |
US6890342B2 (en) * | 2000-08-02 | 2005-05-10 | Loma Linda University | Method and apparatus for closing vascular puncture using hemostatic material |
AU2001295765B2 (en) * | 2000-10-23 | 2006-02-23 | Tissuemed Limited | Self-adhesive hydratable matrix for topical therapeutic use |
US6733774B2 (en) | 2001-01-25 | 2004-05-11 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US7098315B2 (en) | 2001-01-25 | 2006-08-29 | Nycomed Pharma As | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
HU227987B1 (hu) * | 2001-01-25 | 2012-07-30 | Nycomed Pharma As | Szilárd fibrinogént és szilárd trombint tartalmazó hordozó |
US7052713B2 (en) | 2001-02-13 | 2006-05-30 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
WO2003094983A1 (de) * | 2002-05-08 | 2003-11-20 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | Resorbierbare pharmazeutische formulierung zur kontinuierlichen thrombinfreisetzung |
JP4544991B2 (ja) | 2002-06-14 | 2010-09-15 | ローマ リンダ ユニヴァーシティ メディカル センター | 血管の創傷をふさぐ装置および方法 |
US20040106344A1 (en) * | 2002-06-28 | 2004-06-03 | Looney Dwayne Lee | Hemostatic wound dressings containing proteinaceous polymers |
EP1573295A2 (en) | 2002-12-11 | 2005-09-14 | Ferrosan A/S | Gelatine-based materials as swabs |
US20040122349A1 (en) | 2002-12-20 | 2004-06-24 | Lafontaine Daniel M. | Closure device with textured surface |
US8709038B2 (en) | 2002-12-20 | 2014-04-29 | Boston Scientific Scimed, Inc. | Puncture hole sealing device |
WO2004064878A1 (ja) * | 2003-01-20 | 2004-08-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 止血用材料 |
AU2004226578A1 (en) * | 2003-04-04 | 2004-10-14 | Tissuemed Limited | Tissue-adhesive formulations |
US8834864B2 (en) | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US7942897B2 (en) | 2003-07-10 | 2011-05-17 | Boston Scientific Scimed, Inc. | System for closing an opening in a body cavity |
US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
WO2005016152A2 (en) | 2003-08-14 | 2005-02-24 | Loma Linda University Medical Center | Vascular wound closure device |
US8187627B2 (en) * | 2003-09-05 | 2012-05-29 | Loma Linda University Medical Center | Dressing delivery system for internal wounds |
ATE475434T1 (de) | 2004-01-30 | 2010-08-15 | Ferrosan As | Hämostatische sprays und zusammensetzungen |
WO2005113030A1 (ja) * | 2004-05-21 | 2005-12-01 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 組織閉鎖剤 |
WO2006005340A1 (en) | 2004-07-09 | 2006-01-19 | Ferrosan A/S | Haemostatic composition comprising hyaluronic acid |
CA2575943A1 (en) * | 2004-08-03 | 2006-02-09 | Tissuemed Limited | Tissue-adhesive materials |
US20060258995A1 (en) * | 2004-10-20 | 2006-11-16 | Pendharkar Sanyog M | Method for making a reinforced absorbable multilayered fabric for use in medical devices |
US20060257457A1 (en) * | 2004-10-20 | 2006-11-16 | Gorman Anne J | Method for making a reinforced absorbable multilayered hemostatic wound dressing |
BRPI0516220B8 (pt) * | 2004-10-20 | 2021-06-22 | Ethicon Inc | tecido de multicamadas absorvíveis reforçadas para aplicação em dispositivos médicos e método de fabricação |
US9358318B2 (en) * | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
US20060093655A1 (en) * | 2004-10-20 | 2006-05-04 | Lillian Bar | Method for making a reinforced absorbable multilayered hemostatic wound dressing |
AU2005315876A1 (en) * | 2004-12-14 | 2006-06-22 | Fidia Advanced Biopolymers S.R.L. | Process for the preparation of two and three dimensional polymer scaffolds |
US20060142798A1 (en) * | 2004-12-27 | 2006-06-29 | Holman Thomas J | Device and method for closing an opening in a body cavity or lumen |
JP5204646B2 (ja) | 2005-04-25 | 2013-06-05 | マサチューセッツ インスティテュート オブ テクノロジー | 止血および他の生理学的活性を促進するための組成物および方法 |
JP2006306759A (ja) * | 2005-04-27 | 2006-11-09 | Fujimori Kogyo Co Ltd | トロンビン医薬製剤 |
US7429241B2 (en) | 2005-09-29 | 2008-09-30 | Codman & Shurtleff, Inc. | Dural graft and method of preparing the same |
CN101495047B (zh) | 2005-10-05 | 2011-12-28 | 洛马林达大学医学中心 | 血管伤口封闭装置及方法 |
KR20080102152A (ko) | 2006-02-03 | 2008-11-24 | 티슈메드 리미티드 | 조직-접착 물질 |
US20090018575A1 (en) * | 2006-03-01 | 2009-01-15 | Tissuemed Limited | Tissue-adhesive formulations |
CN101448535B (zh) | 2006-03-23 | 2011-10-19 | 宾州研究基金会 | 带有可膨胀叶轮泵的心脏辅助装置 |
CN101472620A (zh) | 2006-04-25 | 2009-07-01 | 麻省理工学院 | 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法 |
EP2021045B1 (en) | 2006-05-31 | 2016-03-16 | Baxter International Inc. | Collagen for use in prevention of peridural fibrosis formation after spinal surgery |
TWI436793B (zh) | 2006-08-02 | 2014-05-11 | Baxter Int | 快速作用之乾密封膠及其使用和製造方法 |
WO2008019126A2 (en) | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Process for production of solid wound dressing |
EP2111239B1 (en) | 2006-12-15 | 2013-03-06 | Lifebond Ltd. | Gelatin-transglutaminase hemostatic dressings and sealants |
DE102007037051A1 (de) * | 2007-07-24 | 2009-01-29 | Aesculap Ag | Flächiges Implantat |
CL2008003219A1 (es) | 2007-10-30 | 2009-10-09 | Baxter Int | Uso de una biomatriz de colageno biofuncional, multicapas y no porosa, que dirige el crecimiento celular dentro de los intersticios de la biomatriz de colageno, para tratar un defecto de una membrana visceral o parietal; y biomatriz utilizada. |
WO2009109194A2 (en) * | 2008-02-29 | 2009-09-11 | Ferrosan A/S | Device for promotion of hemostasis and/or wound healing |
EP2269594B1 (en) | 2008-04-16 | 2016-03-02 | The Chemo-Sero-Therapeutic Research Institute | Method of producing thrombin-immobilized bioabsorbable sheet preparation |
CN102124058B (zh) | 2008-06-18 | 2014-05-28 | 生命连结有限公司 | 改进的交联组合物 |
CN105435211A (zh) | 2008-10-06 | 2016-03-30 | 三维肽胶株式会社 | 组织闭塞剂 |
WO2010084481A1 (en) | 2009-01-23 | 2010-07-29 | Royal College Of Surgeons In Ireland | Layered scaffold suitable for osteochondral repair |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
JP5675607B2 (ja) * | 2009-06-11 | 2015-02-25 | 一般財団法人化学及血清療法研究所 | 創傷被覆材 |
US9162006B2 (en) | 2009-06-16 | 2015-10-20 | Baxter International Inc. | Hemostatic sponge |
EP2477617B1 (en) | 2009-09-18 | 2018-01-31 | Bioinspire Technologies Inc. | Free-standing biodegradable patch |
US9271925B2 (en) | 2013-03-11 | 2016-03-01 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
DE102009053305A1 (de) | 2009-11-12 | 2011-08-18 | medichema GmbH, 09112 | Verfahren zur Herstellung einer schichtförmigen Wundauflage |
US9439941B2 (en) | 2009-12-14 | 2016-09-13 | The University Of Hong Kong | Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells |
CA2784432C (en) * | 2009-12-16 | 2019-01-15 | Baxter Healthcare S.A. | Hemostatic sponge |
AU2010334412B2 (en) | 2009-12-22 | 2016-02-04 | Lifebond Ltd | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
EP2547371A1 (en) * | 2010-03-15 | 2013-01-23 | Ferrosan Medical Devices A/S | A method for promotion of hemostasis and/or wound healing |
SA111320355B1 (ar) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | إسفنجة لايقاف النزف |
EP2575770B1 (en) | 2010-06-01 | 2017-03-22 | Baxter International Inc | Process for making dry and stable hemostatic compositions |
BR112012030457B1 (pt) | 2010-06-01 | 2021-03-09 | Baxter International Inc. | processo para fabricar uma composição hemostática seca e estável, recipiente acabado final, método para prover uma composição hemostática pronta para uso, e, kit para administrar uma composição hemostática |
KR101814841B1 (ko) | 2010-06-01 | 2018-01-03 | 백스터 인터내셔널 인코포레이티드 | 건조 및 안정한 지혈 조성물의 제조 방법 |
CN103096944A (zh) * | 2010-07-20 | 2013-05-08 | 一般财团法人化学及血清疗法研究所 | 组织粘合用片制剂 |
AU2011287215B2 (en) | 2010-08-05 | 2015-09-10 | Lifebond Ltd. | Dry composition wound dressings and adhesives |
DE102010038155A1 (de) | 2010-10-05 | 2012-04-05 | Technische Universität Ilmenau | Einem biologischen Gewebe nachgebildete Struktur und Verfahren zu deren Herstellung |
CN102357259A (zh) * | 2011-07-28 | 2012-02-22 | 王珊珊 | 一种生物蛋白海绵及其制备方法 |
WO2013048787A1 (en) | 2011-09-26 | 2013-04-04 | Yes, Inc. | Novel hemostatic compositions and dressings for bleeding |
EP4137164A1 (en) | 2011-10-11 | 2023-02-22 | Baxter International Inc. | Hemostatic compositions |
CA2851321C (en) | 2011-10-11 | 2020-07-07 | Baxter International Inc. | Hemostatic compositions |
AU2012330450B2 (en) | 2011-10-27 | 2017-04-27 | Baxter Healthcare Sa | Hemostatic compositions |
EP2822474B1 (en) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
EP2825216B1 (en) | 2012-06-12 | 2015-08-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
AU2013286676B2 (en) | 2012-07-06 | 2016-12-15 | 3-D Matrix, Ltd. | Fill-finish process for peptide solutions |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
IL229645A0 (en) * | 2013-11-26 | 2014-03-31 | Omrix Biopharmaceuticals Ltd | A dry bandage containing thrombin and pectin |
JP6489485B2 (ja) | 2013-12-11 | 2019-03-27 | フェロサン メディカル デバイシーズ エイ/エス | 押し出し増強因子を含んでいる乾燥組成物 |
ES2712608T3 (es) | 2014-03-10 | 2019-05-14 | 3 D Matrix Ltd | Péptidos autoensamblantes para el tratamiento de las bullas pulmonares |
WO2015136370A2 (en) | 2014-03-10 | 2015-09-17 | 3-D Matrix, Ltd. | Sterilization and filtration of peptide compositions |
BR112016020584A2 (pt) | 2014-03-10 | 2017-10-03 | 3 D Matrix Ltd | Composições de peptídeo auto-organizável |
DE102014106711A1 (de) | 2014-05-13 | 2015-11-19 | Bayer Innovation Gmbh | Verwendung von siliziumhaltigen Fasern und/oder einer Fasermatrix als bioresorbierbares Wundvlies |
KR101536134B1 (ko) * | 2014-09-26 | 2015-07-14 | 세원셀론텍(주) | 연부조직 수복용 매트릭스의 제조방법 |
JP6726852B2 (ja) | 2014-10-13 | 2020-07-22 | フェッローサン メディカル ディバイス エー/エス | 止血および創傷治癒に使用するための乾燥組成物 |
CN107206165B (zh) | 2014-12-24 | 2020-10-23 | 弗罗桑医疗设备公司 | 用于保持并混合第一和第二物质的注射器 |
KR101664415B1 (ko) * | 2015-01-12 | 2016-10-12 | 주식회사 한국비엔씨 | 약물을 포함하는 콜라겐 창상피복재 및 이의 제조방법 |
US11434469B2 (en) | 2015-02-10 | 2022-09-06 | Lifenet Health | Biologically functional soft tissue scaffolds and implants |
KR20170125061A (ko) * | 2015-02-27 | 2017-11-13 | 폴리가닉스 아이피 비.브이. | 약물 용출 발포체 및 그 제조 |
JP6747651B2 (ja) | 2015-07-03 | 2020-08-26 | フェロサン メディカル デバイシーズ エイ/エス | 保管状態で真空を保持するための、及び2種の成分を混合するためのシリンジ |
WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
US20210128778A1 (en) | 2017-03-09 | 2021-05-06 | Baxter International Inc. | Solvent deposition system and methods |
RU176884U1 (ru) * | 2017-09-25 | 2018-01-31 | Павел Борисович Панов | Кровоостанавливающий пакет |
CN111712230B (zh) | 2017-12-15 | 2024-04-26 | 立美基股份有限公司 | 表面活性剂肽纳米结构及在药物递送中的用途 |
KR20210008479A (ko) | 2018-05-09 | 2021-01-22 | 훼로산 메디칼 디바이스 에이/에스 | 지혈 조성물을 제조하는 방법 |
US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
RU2701195C1 (ru) * | 2018-11-28 | 2019-09-25 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) | Способ получения искусственных губок в микропробирках для проведения лабораторных исследований in vitro |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1717118A1 (de) * | 1964-05-16 | 1972-10-19 | Spofa Vereinigte Pharma Werke | Verfahren zur Herstellung von Kollagenschaum |
US3514518A (en) * | 1967-12-19 | 1970-05-26 | Pierre Charier Vadrot | Process for preparation of gelatinous material from animal collagen |
US3823212A (en) * | 1968-11-27 | 1974-07-09 | Freudenberg C Fa | Process for the production of collagen fiber fabrics in the form of felt-like membranes or sponge-like layers |
US4390519A (en) * | 1978-05-19 | 1983-06-28 | Sawyer Philip Nicholas | Bandage with hemostatic agent and methods for preparing and employing the same |
US4404970A (en) * | 1978-05-19 | 1983-09-20 | Sawyer Philip Nicholas | Hemostatic article and methods for preparing and employing the same |
US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
DE3019612A1 (de) * | 1980-05-22 | 1981-11-26 | Boehringer Mannheim Gmbh, 6800 Mannheim | Stabilisiertes thrombinpraeparat |
CA1156529A (en) * | 1980-06-12 | 1983-11-08 | Fred A. Serravallo | Fibrous collagenous hemostatic-adhesive webs |
US4292972A (en) * | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
DE3037513C2 (de) * | 1980-10-03 | 1983-05-05 | Steffan, Wolfgang, 8425 Neustadt | Kollagene Wundauflage |
DE3105624A1 (de) * | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | Material zum abdichten und heilen von wunden |
DE3212412C2 (de) * | 1982-04-02 | 1986-01-02 | Dr. Ruhland Nachf. GmbH, 8425 Neustadt | Gewebeverklebbare kollagene Wundauflage |
US4515637A (en) * | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
US4600574A (en) * | 1984-03-21 | 1986-07-15 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of producing a tissue adhesive |
US4925924A (en) * | 1984-03-27 | 1990-05-15 | University Of Medicine And Dentistry Of New Jersey | Biocompatible synthetic and collagen compositions having a dual-type porosity for treatment of wounds and pressure ulcers and therapeutic methods thereof |
US4606910A (en) * | 1984-06-28 | 1986-08-19 | Interface Biomedical Laboratories | Composite hemostatic article including a hemostatic agent onlay and methods for preparing the same |
DE3533423A1 (de) | 1985-09-19 | 1987-03-26 | Wolf Gmbh Richard | Applikator-zangeneinsatz fuer chirurgische handhabe zur anwendung in der endoskopie |
US4696812A (en) * | 1985-10-28 | 1987-09-29 | Warner-Lambert Company | Thrombin preparations |
ZA88227B (en) * | 1987-01-28 | 1988-06-30 | Warner-Lambert Company | Thrombin preparations |
JPS6440433A (en) * | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
US4891359A (en) | 1988-12-08 | 1990-01-02 | Johnson & Johnson Patient Care, Inc. | Hemostatic collagen paste composition |
DK223389D0 (da) | 1989-05-05 | 1989-05-05 | Ferrosan As | Saarsvamp |
JPH039747U (ja) * | 1989-06-20 | 1991-01-30 | ||
FR2679778B1 (fr) * | 1991-08-02 | 1995-07-07 | Coletica | Utilisation de collagene reticule par un agent de reticulation pour la fabrication d'une membrane suturable, biocompatible, a resorption lente, ainsi qu'une telle membrane. |
US5331092A (en) * | 1992-11-06 | 1994-07-19 | Coletica | Process of preparation of collagen containing in major proportion insoluble collagen and collagen having high mechanical resistance and thermal stability obtained thereby |
JP3172289B2 (ja) | 1992-11-18 | 2001-06-04 | 三洋電機株式会社 | 熱交換ユニット |
US5836970A (en) * | 1996-08-02 | 1998-11-17 | The Kendall Company | Hemostatic wound dressing |
-
1997
- 1997-04-02 AU AU26359/97A patent/AU726163B2/en not_active Expired
- 1997-04-02 DE DE69724243T patent/DE69724243T2/de not_active Expired - Lifetime
- 1997-04-02 JP JP09535819A patent/JP2000510357A/ja not_active Withdrawn
- 1997-04-02 CA CA002251475A patent/CA2251475C/en not_active Expired - Lifetime
- 1997-04-02 AT AT97918102T patent/ATE247494T1/de not_active IP Right Cessation
- 1997-04-02 CZ CZ983189A patent/CZ318998A3/cs unknown
- 1997-04-02 SK SK1373-98A patent/SK284693B6/sk not_active IP Right Cessation
- 1997-04-02 EP EP97918102A patent/EP0891193B1/en not_active Expired - Lifetime
- 1997-04-02 HU HU9903586A patent/HUP9903586A3/hu unknown
- 1997-04-02 WO PCT/EP1997/001662 patent/WO1997037694A1/en not_active Application Discontinuation
- 1997-04-02 RU RU98119893/14A patent/RU2193897C2/ru not_active IP Right Cessation
- 1997-04-02 US US09/155,569 patent/US6649162B1/en not_active Expired - Lifetime
-
1998
- 1998-10-02 NO NO19984619A patent/NO314070B1/no not_active IP Right Cessation
-
2009
- 2009-10-29 JP JP2009248693A patent/JP5373553B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2635997A (en) | 1997-10-29 |
JP2010046516A (ja) | 2010-03-04 |
NO314070B1 (no) | 2003-01-27 |
DE69724243T2 (de) | 2004-06-17 |
CA2251475A1 (en) | 1997-10-16 |
WO1997037694A1 (en) | 1997-10-16 |
HUP9903586A3 (en) | 2003-02-28 |
EP0891193A1 (en) | 1999-01-20 |
NO984619D0 (no) | 1998-10-02 |
NO984619L (no) | 1998-12-03 |
HUP9903586A2 (hu) | 2000-03-28 |
EP0891193B1 (en) | 2003-08-20 |
SK137398A3 (en) | 1999-03-12 |
SK284693B6 (sk) | 2005-09-08 |
RU2193897C2 (ru) | 2002-12-10 |
JP2000510357A (ja) | 2000-08-15 |
AU726163B2 (en) | 2000-11-02 |
DE69724243D1 (de) | 2003-09-25 |
CZ318998A3 (cs) | 1999-09-15 |
US6649162B1 (en) | 2003-11-18 |
ATE247494T1 (de) | 2003-09-15 |
CA2251475C (en) | 2006-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5373553B2 (ja) | コラーゲンを基にした止血スポンジ | |
US20210228764A1 (en) | Hemostatic sponge | |
US20230092332A1 (en) | Hemostatic sponge | |
JP5719355B2 (ja) | 止血スポンジ | |
JP2020509802A (ja) | 溶媒デポジションシステム及び方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091130 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121211 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130204 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130711 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130725 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130827 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130919 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |